Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on Clostridium difficile-induced colitis, Part 2

C M Reinke1, C R Messick

  • 1Department of Clinical Pharmacy Practice, School of Pharmacy, Auburn University, AL 36849-5502.

American Journal of Hospital Pharmacy
|August 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobes.

Antimicrobial agents and chemotherapy·2000
Same author

Modified time-kill assay against multidrug-resistant Enterococcus faecium with novel antimicrobial combinations.

The Journal of antimicrobial chemotherapy·1999
Same author

In-vitro activity of polyhexamethylene biguanide (PHMB) against fungal isolates associated with infective keratitis.

The Journal of antimicrobial chemotherapy·1999
Same author

In vitro activity of RPR 106972 alone and in combination with vancomycin, ampicillin, and gentamicin against multidrug-resistant enterococci.

Diagnostic microbiology and infectious disease·1998
Same author

Levofloxacin and sparfloxacin: new quinolone antibiotics.

The Annals of pharmacotherapy·1998
Same author

Pharmacoeconomic analysis of ampicillin-sulbactam versus cefoxitin in the treatment of intraabdominal infections.

Pharmacotherapy·1998
Same journal

National health care reform, Part 2: Response to pharmacists.

American journal of hospital pharmacy·1994
Same journal

Validity of originality assessment.

American journal of hospital pharmacy·1994
Same journal

Unit dose dispensing of chromic phosphate P 32 suspension.

American journal of hospital pharmacy·1994
Same journal

Hydralazine injection still available.

American journal of hospital pharmacy·1994
Same journal

Improved extemporaneous formulation of cyclosporine ophthalmic drops.

American journal of hospital pharmacy·1994
Same journal

Paclitaxel diluent and the case of the slippery spike.

American journal of hospital pharmacy·1994
See all related articles

Oral metronidazole is the preferred treatment for Clostridioides difficile infection (CDI), offering equivalent efficacy to vancomycin for most cases. Vancomycin should be reserved for severe CDI or refractory cases, minimizing resistance risks.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Clostridioides difficile (C. diff) is a significant nosocomial pathogen causing antibiotic-associated diarrhea.
  • Factors like poor hygiene, antimicrobial exposure, and antineoplastic agents contribute to C. diff infections (CDI).
  • Clinical presentations of CDI range from mild diarrhea to severe, life-threatening conditions like pseudomembranous colitis (PMC).

Purpose of the Study:

  • To compare the therapeutic equivalence of oral metronidazole and oral vancomycin for treating Clostridioides difficile infection (CDI).
  • To provide treatment recommendations based on disease severity and cost-effectiveness.
  • To address the implications of vancomycin use on the emergence of antibiotic resistance.

Main Methods:

Related Experiment Videos

  • Review and synthesis of existing data on the efficacy of oral metronidazole and vancomycin for CDI.
  • Analysis of clinical presentation and severity in relation to treatment outcomes.
  • Consideration of factors such as cost, patient tolerance, and potential for resistance development.

    • Main Results:

    • Oral metronidazole and oral vancomycin demonstrate comparable therapeutic efficacy for non-severe CDI.
    • The optimal treatment for severe CDI remains controversial, requiring further research.
    • Oral metronidazole is recommended as the first-line treatment due to cost-effectiveness.

    Conclusions:

    • Oral metronidazole should be the preferred initial therapy for most CDI cases.
    • Oral vancomycin is reserved for severe or metronidazole-refractory CDI.
    • Limiting institutional vancomycin use may help mitigate the risk of vancomycin-resistant enterococci emergence.